顺铂分别联合诺维本、健择、泰索帝治疗晚期非小细胞肺癌的临床研究  

Clinical study of cisplatin combined with Vinorelbine、Gemzar and Docetaxel in treatment of advanced non-small cell lung cancer

作　　者：宋扬[1] 冯英明[1] 张贺龙[1] 姬统理[1] 闵婕[1] 王宏[1] 

机构地区：[1]第四军医大学唐都医院肿瘤科,陕西西安710038

出　　处：《现代肿瘤医学》2005年第4期494-496,共3页Journal of Modern Oncology

摘　　要：目的探讨含顺铂的三种联合化疗方案治疗晚期非小细胞肺癌的近期疗效及不良反应。方法应用诺维本(NVB)、健择(GEM)、泰索帝(TXT)分别与顺铂(DDP)组成两药联合方案(NP、GP、TP)治疗Ⅲ～Ⅳ期非小细胞肺癌共78例,其中NP组31例,GP组22例,TP组25例,3组病例的临床资料具有可比性。结果NP、GP、TP组有效率分别为29%(9/31)、36%(8/22)和40%(10/25),3组间近期疗效无显著差异(P>0.05)。不良反应主要为骨髓抑制,其中Ⅲ～Ⅳ度白细胞减少发生率3组分别为32%(10/31)、27%(6/22)和28%(7/25),各组间比较无统计学意义(P>0.05)。结论诺维本、健择、泰索帝与顺铂分别组成两药联合方案对晚期非小细胞肺癌均有确切疗效,组间无明显差异,均可作为一线治疗方案应用。Objective To evaluate the effect and side reaction of three DDP-containing combined chemotherapy regimens in treatment of advanced non-small cell lung cancer(NSCLC).Methods Three DDP-containing combined chemotherapy regimens: NVB and DDP regimen(NP),GEM and DDP regimen(GP),TXT and DDP regimen(TP),were used to treat 78 patients of non-small cell lung cancer at stage Ⅲ～Ⅳ.31 patients were treated with NP,22 patients with GP and 25 patients with TP.Patients in three groups were well-matched in basic characteristics.Results The reponse rate was 29%(9/31) in group NP, 36%(8/22) in group GP and 40%(10/25) in group TP.The efficacy in three groups had no significant difference (P>0.05).The main side reaction was hematologic toxicity.Conclusion DDP combined with NVB、GEM or TXT have definite efficacy in the patients with non-small cell lung cancer.There was no obvious difference among the three groups.All the three regimens can be applied to the first line chemotherapy.

关 键 词：非小细胞肺癌 顺铂 诺维本 健择 泰索帝 

分 类 号：R734.2[医药卫生—肿瘤]